Legato Capital Management LLC Has $1.63 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Legato Capital Management LLC decreased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 5.1% in the fourth quarter, Holdings Channel reports. The fund owned 32,316 shares of the biotechnology company’s stock after selling 1,725 shares during the period. Legato Capital Management LLC’s holdings in Corcept Therapeutics were worth $1,628,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Creative Planning increased its holdings in shares of Corcept Therapeutics by 18.2% during the 2nd quarter. Creative Planning now owns 11,626 shares of the biotechnology company’s stock worth $378,000 after purchasing an additional 1,794 shares during the period. Cetera Investment Advisers increased its holdings in shares of Corcept Therapeutics by 6.2% during the 2nd quarter. Cetera Investment Advisers now owns 38,292 shares of the biotechnology company’s stock worth $1,244,000 after purchasing an additional 2,244 shares during the period. CWM LLC increased its holdings in shares of Corcept Therapeutics by 81.5% during the 3rd quarter. CWM LLC now owns 8,976 shares of the biotechnology company’s stock worth $415,000 after purchasing an additional 4,030 shares during the period. nVerses Capital LLC increased its holdings in shares of Corcept Therapeutics by 43.6% during the 3rd quarter. nVerses Capital LLC now owns 5,600 shares of the biotechnology company’s stock worth $259,000 after purchasing an additional 1,700 shares during the period. Finally, AlphaMark Advisors LLC increased its holdings in shares of Corcept Therapeutics by 2,269.6% during the 3rd quarter. AlphaMark Advisors LLC now owns 9,739 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 9,328 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.72, for a total transaction of $80,031.92. Following the completion of the transaction, the insider now owns 8,494 shares in the company, valued at approximately $481,779.68. This trade represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,811 shares of company stock worth $1,329,832 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

CORT has been the topic of a number of analyst reports. StockNews.com cut shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research note on Friday, February 7th. Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Finally, Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $68.11 on Wednesday. The firm has a market cap of $7.14 billion, a PE ratio of 54.06 and a beta of 0.58. Corcept Therapeutics Incorporated has a 12 month low of $20.84 and a 12 month high of $71.29. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $57.27 and its two-hundred day moving average price is $48.73.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.